Abstract: The present invention relates to the use of carbachol and other cholinergic substances for the treatment of keratoconjunctivitis sicca.

Abstract: Disclosed are the 22R and 22S epimers of compounds of the formula ##STR1## wherein X.sub.1 represents a fluorine atom, and X.sub.2 represents a hydrogen atom or a fluorine atom. Also disclosed are processes for the preparation of the compounds, pharmaceutical compositions comprising the compounds and methods of treatment of inflammatory and allergic conditions employing the compounds.

Abstract: Effective amounts of formoterol and/or a physiologically acceptable salt and/or solvate thereof and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory respiratory disorder, such as asthma.

Abstract: The invention relates to a method for treating the surface of surgical implants made of titanium or a titanium alloy, for instance dental implants, before implantation in bone tissue. The method results in a roughened exterior implant surface and at the same time a cleaning action is obtained, should there be any contaminants. The surface is blasted with particles of an oxide of titanium, preferably titanium dioxide. In this way an implant having an improved retention in bone tissue is obtained. The Blasted implant is used in a method for treating toothlessness.

Abstract: The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA of general formula (I), wherein R.sup.1 and R.sup.2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R.sup.3, R.sup.4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R.sup.5 wherein Z is selected from CH.sub.n, NH.sub.m, O, S, SO.sub.2 and CO wherein n=1 or 2; m=0 or 1 and R.sup.5 is selected from alkyl, aryl and fluoroalkyl; or R.sup.3 and R.sup.4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C.sub.1 -C.sub.3 alkylene or alkenylene, --N.dbd., --N.dbd.N-- and (a), wherein R.sub.7 .dbd.

Abstract: The present invention is related to a pharmaceutical formulation which is an oil-in-water emulsion for parenteral and oral use which comprises(i) an emulsion-stabilizing surface active drug in high concentration;(ii) optionally a pharmacologically inert oil;(iii) optionally a surfactant;(iv) water or a buffer; and(v) an agent giving isotonicity to the final formulation;the use of and a process for preparation of the formulation.

Abstract: The invention relates to a disposable breath-actuated inhaler comprising a housing forming an air flow path open at both ends, wherein one end forms an air inlet and one end forms an air outlet. The housing includes a compartment for storing a pharmaceutical powder to be inhaled which is located close to the air inlet and covered by a thin foil which seals the compartment in an airtight way. The foil can be removed from the compartment from outside the housing. Additionally, the housing has a constriction adjacent the powder compartment such that a turbulent air stream will be obtained at the constriction upon inhalation which will lift the powder out from the compartment and mix the powder into the air stream.

Abstract: A process for the production of guanidino protected .omega.-aminoalkyl guanidines comprising reacting a diamine selectively at one amino group with an alkoxycarbonyl or aralkoxycarbonyl protected electrophilic guanylation reagent. The process of the invention is general and may be performed efficiently in one step yielding a product with high purity and in useful yields. The invention further refers to some compounds that are novel per se and to some novel compounds useful in the process of the invention.

Abstract: 3-amino-5-carbonylchromans, as well as enantiomers and salts thereof are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

Abstract: A method is disclosed for the treatment of anxiety by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Abstract: 2-amino-N-(1,2-diphenyl-1-methylethyl) acetamide (remacemide) or a phamaceutically acceptable salt thereof, and L-dopa, are useful in conjunction with one another in the treatment of Parkinson's disease. Pharmaceutical products and formulations comprising these active agents are provided.

Abstract: A process for preparing (R)-3-amino-5-methoxychroman is provided. The process comprises the steps of (i) dissolving racemic 3-amino-5-methoxychroman and L(+)tartaric acid in water to form the tartrate salt; (ii) heating the solution until a clear solution is obtained; and (iii) crystallizing the tartrate salt by allowing the solution to cool to room temperature.

Abstract: New crystalline organic salts of N,N'-diacetyl cystine with immunomodulating effect, processes for their preparation, pharmaceutical compositions containing them and methods of their pharmacological use.

Abstract: A process is described for the preparation of 4-Methyl-5-(2-Chloroalkyl)-thiazole wherein the alkyl ranges from C.sub.2 -C.sub.5, by providing the steps of either a) converting the 3-thiocyanato-5-chloro-2-alkanone into 2-chloro-4-methyl-5-(2-chloroalkyl)-thiazole by gaseous hydrochloric acid in an organic solvent and hydrogenating the compound in the presence of a metal catalyst in an organic solvent, or b) reacting 3-thiocyanato-5-choro-2-alkanone with aqueous mineral acid and treating the thiazole obtained with a halogenating agent, and hydrogenating the 2-chloro-4-methyl-5-(2-chloroalkyl)-thiazole in an organic solvent in presence of a metal catalyst.

Abstract: Compounds of the formula ##STR1## are disclosed. These compounds are employed as intermediates in the synthesis of aminochroman compounds useful in the treatment of CNS disorders.

Abstract: The invention relates to a joint prosthesis for permanent anchorage in the bone tissue of one of the articulatory parts of a joint in a human body, in particular the femur side of a knee joint, primarily intended to be fitted in one operation only. The prosthesis comprises an attachment part (1), intended to be anchored in the human bone tissue by means of a fixture (8), and an articulation element (2) adapted to fit the attachment part (1). The articulation element is attached to the attachment part by a combination of complementary shapes (27, 28, 33, 34) and snap-action locking means (31).

Abstract: An oral pharmaceutical composition is described for targeted slow release in the treatment of inflammatory bowel diseases. Also described are pharmaceutical compositions for peroral treatment targeted to different areas of the intestinal tract afflicted by ulcerative colitis and certain aspects of Crohn's disease.

Abstract: A method is disclosed for the treatment of depression by the administration of 3-amino-5-carbamoylchromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Abstract: 3-amino-5-aryl- and 5-heteroarylchromans, as well as enantiomers and salts thereof are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.